Articles from China Medical System Holdings Limited

CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies

By China Medical System Holdings Limited · Via ACN Newswire · June 22, 2026

CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

By China Medical System Holdings Limited · Via ACN Newswire · June 8, 2026

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer(R) and Cosmofer(R)

By China Medical System Holdings Limited · Via ACN Newswire · April 27, 2026

CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

By China Medical System Holdings Limited · Via ACN Newswire · April 23, 2026

CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets

By China Medical System Holdings Limited · Via ACN Newswire · July 21, 2025